Merck & Co., Inc.
MRKFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Merck & Co., Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 19 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 2, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
No 13F rows are listed for Merck & Co., Inc.
- Each value is checked against Merck & Co., Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- 20 rows left out: the value per share they report is far from Merck & Co., Inc.'s share prices on file from around the report date, far from the value most filers reported for that date, or the value of a security already left out, so they may describe another security or share class.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Merck & Co., Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-02-09 · Zachary Jennifer: Larger than all 21 other insider sales of Common Stock on file. SEC filing
- 2026-02-09 · Zachary Jennifer: Larger than 19 of the 21 other insider sales of Common Stock on file. SEC filing
- 2026-02-04 · Litchfield Caroline: Larger than 20 of the 21 other insider sales of Common Stock on file. SEC filing
Independent insiders buying near the same time
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-02-12 | Guindo Chirfi · Chief Marketing Officer | Common Stock | S — Open market or private sale | −10,000 | 121.46 | SEC filing |
| 2026-02-10 | Li Dean Y · Executive VP & President, MRL | Common Stock | S — Open market or private sale | −10,235 | 117.52 | SEC filing |
| 2026-02-09 | Zachary Jennifer · EVP, General Counsel | Common Stock | S — Open market or private sale | −38,835 | 119.15 | SEC filing |
| 2026-02-09 | Guindo Chirfi · Chief Marketing Officer | Common Stock | S — Open market or private sale | −10,000 | 118.41 | SEC filing |
| 2026-02-09 | Zachary Jennifer · EVP, General Counsel | Common Stock | S — Open market or private sale | −56,792 | 119.15 | SEC filing |
| 2026-02-09 | Zachary Jennifer · EVP, General Counsel | Common Stock | S — Open market or private sale | −25,946 | 119.15 | SEC filing |
| 2026-02-06 | Williams David Michael · EVP,Chief Info&Digital Officer | Common Stock | S — Open market or private sale | −5,000 | 121.91 | SEC filing |
| 2026-02-06 | DeLuca Richard R. · EVP&Pres, Merck Animal Heallth | Common Stock | S — Open market or private sale | −37,685 | 120.92 | SEC filing |
Showing 8 of 12 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-05-29 | Rothman Paul · Director | Phantom Stock | A — Grant, award, or other acquisition | +1,853 | SEC filing |
| 2026-05-29 | Craig Pamela J. · Director | Phantom Stock | A — Grant, award, or other acquisition | +1,853 | SEC filing |
| 2026-05-29 | Warden Kathy J · Director | Phantom Stock | A — Grant, award, or other acquisition | +1,853 | SEC filing |
| 2026-05-29 | GLOCER THOMAS H · Director | Phantom Stock | A — Grant, award, or other acquisition | +1,853 | SEC filing |
| 2026-05-29 | THULIN INGE G · Director | Phantom Stock | A — Grant, award, or other acquisition | +1,853 | SEC filing |
| 2026-05-29 | Karsanbhai Surendralal Lanca · Director | Phantom Stock | A — Grant, award, or other acquisition | +1,853 | SEC filing |
| 2026-05-29 | Coe Mary Ellen · Director | Phantom Stock | A — Grant, award, or other acquisition | +1,853 | SEC filing |
| 2026-05-29 | Seidman Christine E · Director | Phantom Stock | A — Grant, award, or other acquisition | +1,853 | SEC filing |
Showing 8 of 30 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.